Physician profile
Devon Noel Napierkowski
NPI 1285391367
$4,128.36
in general payments reported to CMS, 2019-2025
35 companies · $1,168 in 2025
The $1,168 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $338 · 2023: $888 · 2024: $1,735 · 2025: $1,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217 · Education: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.17 |
| Education | $573.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $618.18 | 2022-2025 | Lynparza, Imfinzi, Calquence |
| Novartis Pharmaceuticals Corporation | $462.09 | 2023-2025 | |
| Janssen Biotech, INC. | $461.25 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Aveo Pharmaceuticals, INC. | $314.42 | 2022-2025 | |
| Incyte Corporation | $312.57 | 2023-2024 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $244.80 | 2024-2025 | |
| Geron Corporation | $209.27 | 2025 | Rytelo |
| Amgen INC. | $164.17 | 2023-2024 | Kyprolis, Lumakras |
| Exelixis INC. | $147.43 | 2024-2025 | Cabometyx |
| Tempus Ai, INC | $113.05 | 2024-2025 | Xt Cdx |
| Dendreon Pharmaceuticals LLC | $109.79 | 2022-2024 | Provenge |
| Pfizer INC. | $102.73 | 2025 | |
| Genentech USA, INC. | $87.19 | 2024-2025 | Venclexta, Phesgo |
| G1 Therapeutics, INC. | $76.36 | 2023 | Cosela |
| Seagen INC. | $72.73 | 2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $64.65 | 2023 | Opdivo |
| Merck Sharp & Dohme LLC | $55.02 | 2023-2025 | Keytruda, Keytruda Qlex |
| Daiichi Sankyo INC. | $44.48 | 2024 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $44.10 | 2024 | Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $43.47 | 2025 | Libtayo |
| Array Biopharma INC | $41.57 | 2024-2025 | Mektovi, Xalkori, Braftovi |
| Foundation Medicine, INC. | $37.76 | 2023 | |
| Abbvie INC. | $33.44 | 2025 | |
| Adc Therapeutics America, INC. | $30.34 | 2024-2025 | |
| Astellas Pharma US INC | $30.24 | 2025 | Padcev |
| Iovance Biotherapeutics, INC. | $28.86 | 2025 | Amtagvi |
| Bayer Healthcare Pharmaceuticals INC. | $28.73 | 2024 | |
| Pharmaessentia USA Corporation | $27.28 | 2024 | Besremi |
| Ge Healthcare | $22.27 | 2024 | |
| Invivyd INC | $21.77 | 2024 | Pemgarda |
| Novocure INC. | $18.84 | 2024 | Optune Lua (Novottf-200t) |
| Beigene USA, INC. | $15.44 | 2023 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $15.41 | 2022 | |
| Boston Scientific Corporation | $14.95 | 2025 | Farapulse |
| Celgene Corporation | $13.71 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Napierkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.